GlassScriptPhysician profile
Paul S Bierman
NPI 1144245234
$21,927.63
in general payments reported to CMS, 2019-2025
38 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $389 · 2021: $32.95 · 2022: $1,453 · 2023: $1,514 · 2024: $1,709 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,031.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11,819.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,364.87 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,944.61 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Gilead Sciences, INC. | $569.04 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $568.62 | 2019-2025 | Entyvio, Eohilia |
| Olympus America INC. | $361.86 | 2019-2025 | Endoclot Phs, Single Use Electrosurgical Knife Kd-655 |
| Genzyme Corporation | $359.93 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $244.15 | 2019-2025 | Linzess |
| Pfizer INC. | $231.74 | 2019-2025 | |
| Janssen Biotech, INC. | $220.52 | 2022-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $214.43 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $197.75 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $196.08 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $164.35 | 2024-2025 | Omvoh, Zepbound |
| Nestle Healthcare Nutrition INC. | $139.85 | 2022-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $133.63 | 2023-2025 | Amjevita, Uplizna, Avsola |
| Aimmune Therapeutics, INC. | $130.83 | 2024-2025 | Zenpep, Vowst |
| Intercept Pharmaceuticals, INC. | $126.36 | 2022-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $119.55 | 2022-2025 | Dupixent |
| Medtronic USA, INC. | $118.01 | 2020 | |
| Merck Sharp & Dohme LLC | $117.97 | 2020-2024 | Dificid |
| Organon LLC | $85.90 | 2022-2024 | Renflexis |
| Phathom Pharmaceuticals, INC. | $78.90 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $47.75 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.25 | 2023-2024 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $44.22 | 2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $36.81 | 2024-2025 | Iqirvo |
| Medtronic, INC. | $35.85 | 2022-2023 | Linq II |
| Enterra Medical, INC. | $33.15 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $31.29 | 2024 | Idacio |
| Boston Scientific Corporation | $23.85 | 2024 | |
| Daiichi Sankyo INC. | $23.48 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.86 | 2022 | |
| Shield Therapeutics INC | $17.12 | 2023 | Accrufer |
| Capsovision, INC. | $16.45 | 2024 | Capsocam Plus |
| Novo Nordisk INC | $16.41 | 2025 | Wegovy |
| Redhill Biopharma INC. | $13.72 | 2022 | |
| Dova Pharmaceuticals | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bierman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.